Nephro Care closes trading window from July 1 till Q1FY27 results

Nephro Care India Limited has closed its trading window for all Designated Persons effective July 1, 2026, to prevent insider trading ahead of its quarterly financial announcement. The restriction will remain in force until the completion of 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. This measure aligns with the Company's Code of Conduct for Prevention of Insider Trading, framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

The closure of the trading window is a standard compliance procedure implemented during the period leading up to financial results to ensure that no privileged information is used for trading in the company's securities. The specific date for the Board of Directors meeting to approve the unaudited financial results for the quarter ended June 30, 2026, has not yet been finalized and will be communicated in due course.

Key Details

Event	Date / Time
Trading Window Closure Start	July 1, 2026
Trading Window Reopening	48 hours after Q1FY27 results declaration
Quarter Ended	June 30, 2026
Board Meeting Date	To be informed later

The company has requested the National Stock Exchange of India Limited to take the information on record and disseminate it to the market participants. Sougata Sengupta, Company Secretary & Compliance Officer, signed the disclosure on June 22, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.64%	+5.10%	-6.63%	-38.72%	-39.23%	-61.57%

Nephro Care India Limited reported a net profit of ₹336.89 lakh for the financial year ended 31 March 2026, compared to ₹363.89 lakh in the previous year. Revenue from operations for FY26 stood at ₹8,873.48 lakh, a significant increase from ₹4,603.11 lakh in FY25. The Board of Directors approved the audited standalone and consolidated financial results at a meeting held on 27 May 2026.

The statutory auditor, K. K. Chanani & Associates, issued an unmodified opinion on the financial results. The report highlighted an emphasis of matter regarding the write-off of Goods and Service Tax receivable amounting to ₹86.88 lakh of prior years and GST credit of ₹247.87 lakh standing in the books as of 31 March 2026, which is subject to reconciliation as the balance in the GST portal is nil.

Financial Performance

For the quarter ended 31 March 2026, the company recorded a net profit of ₹100.43 lakh on revenue from operations of ₹2,674.63 lakh. Total income for the quarter was ₹2,757.74 lakh, with total expenses at ₹2,627.94 lakh. Earnings per equity share (not annualised) for the quarter was ₹0.61.

Metric	FY26 (₹ lakh)	FY25 (₹ lakh)
Revenue from operations	8,873.48	4,603.11
Total Income	9,028.23	4,755.80
Total Expenses	8,564.41	4,272.87
Profit for the period	336.89	363.89
Earnings per share (₹)	2.04	2.38

Segment Reporting

Income from IPD Services was the primary revenue driver, contributing ₹4,330.48 lakh for the year, followed by OPD Services at ₹2,519.18 lakh and pharmacy sales at ₹2,036.30 lakh. The company also noted the incorporation of a subsidiary, Vivacity Multiple Ventures Private Limited, on 18 December 2025, though it is yet to commence operations.

The Board also approved the appointment of M/s M. Dutta & Associates as the Internal Auditor for the financial year 2026-27 and noted the internal audit report provided by the firm.